Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Rhea-AI Summary
Geron (Nasdaq: GERN) will release fourth quarter and full year 2025 financial results and business highlights before market open on Wednesday, February 25, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time.
Live and archived audio will be available from the Investors and Media section of the company's website at www.geron.com.
Positive
- None.
Negative
- None.
News Market Reaction – GERN
In the Feb 11 session, GERN declined 0.62%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Financial guidance | Positive | +6.7% | 2026 guidance for RYTELO net product revenue and operating expenses. |
| Dec 18 | Inducement grant | Neutral | -0.8% | Inducement stock options for a new hire under Nasdaq Rule 5635(c)(4). |
| Dec 11 | Restructuring plan | Positive | +8.6% | Strategic restructuring with one‑third workforce reduction to lower 2026 expenses. |
| Dec 08 | Clinical data update | Positive | -3.0% | New RYTELO data at ASH 2025 in LR‑MDS and myelofibrosis. |
| Nov 05 | Earnings release | Positive | -5.2% | Q3 2025 revenue growth, narrowed net loss, and lower 2025 opex guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: guidance and restructuring updates saw gains, while strong clinical and earnings updates at times coincided with share declines.
Over the past few months, Geron has reported multiple milestones. On Nov 5, 2025, Q3 2025 results showed $47.2M in RYTELO net product revenue and narrowed net loss, but shares fell 5.22%. A strategic restructuring announced on Dec 11, 2025 targeting a one‑third workforce reduction led to an 8.59% gain. New RYTELO clinical data at ASH 2025 on Dec 8, 2025 saw a 3.05% decline. Financial guidance on Jan 12, 2026 drove a 6.72% rise. Today’s earnings-date notice fits into this cadence of regular investor updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
